Concepedia

K. Nakagawa

KN

1

Publications

48

Citations

1

H-Index

2022

Active since

Affiliations

Bristol-Myers Squibb (Germany)(Current)

K. Nakagawa is an author at Bristol-Myers Squibb (Germany).

Publications per year

2022–2022

1

Publications

1

LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722

Tony Mok, K. Nakagawa, K. Park et al. · Annals of Oncology · 2022 · 48 citations · Full text

Rows per page

1–1 of 1